Off-The-Shelf CAR-T KLN-1010 Associated With Deep Responses in R/R Myeloma

December 10th 2025, 12:12am

By Courtney Flaherty

KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses in multiple myeloma.

A Closet Full of Boobs and the Thought That Caught Me by Surprise

December 9th 2025, 10:00pm

By Bonnie Annis

After cancer, even your closet tells a story you never imagined living. One quiet afternoon, that story took a hilarious and unexpected turn.

Yescarta Shows Durable Responses and Manageable Safety in Real-World R/R FL

December 9th 2025, 9:10pm

By Alex Biese

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Dexamethasone May Ease Severe Neurotoxicity With Yescarta in LBCL

December 9th 2025, 6:10pm

By Bridget Hoyt

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

New Data Support Pelabresib Combination in Untreated Myelofibrosis

December 9th 2025, 5:29pm

By Paige Britt

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.

Tecvayli Treatment Combo Improves Outcomes in Relapsed/Refractory Myeloma

December 9th 2025, 4:47pm

By Jason Broderick

Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.

Jaypirca Significantly Improves PFS Outcomes in Untreated CLL/SLL

December 9th 2025, 4:03pm

By Sabrina Serani

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL.

Breaking Down the Prostate Cancer Treatment Renaissance

December 9th 2025, 2:00pm

By Dr. Kai Tsao

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Insights Into What’s New in Blood Cancer Care

December 8th 2025, 10:00pm

By Ryan Scott

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

Epkinly Plus Chemo Elicits Durable Responses in DLBCL

December 8th 2025, 9:00pm

By Dr. Josh Brody

Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.

Zervyteg Shows Strong Responses in Acute Graft-Versus-Host Disease

December 8th 2025, 8:30pm

By Andrea Eleazar, MHS

Zervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

December 8th 2025, 3:54pm

By Jason Broderick

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

December 8th 2025, 2:54pm

By Dr. Robert Orlowski

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

What I Want You to Know about Lynch Syndrome

December 8th 2025, 2:00pm

By Georgia Hurst

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

December 7th 2025, 7:58pm

By Jason M Broderick

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.